Mestnaya in\"ektsionnaya terapiya bolezni Peyroni


Cite item

Full Text

References

  1. Lue T. F., Gelbard M. K., Gueglio G. et al. Peyronie's disease. In: Jardin A., Wagner G., Khoury S. et al. Erectile dysfunction. First International consultation on erectile dysfunction. Plymouth: Plymbridge Distributors; 2000. 439-476.
  2. Lindsay M. B., Schain D. M. et al The incidence of Peyronie's disease in Rochester, Minnesota, 1950 through 1984. J. Urol. (Baltimore) 1991; 146: 1007-1009.
  3. Sommer F. Epidemiology of Peyronie's disease. Int. J. Impotence Res. 2002; 14: 379-383.
  4. Горпинченко И. И., Гуженко Ю. Н. Ультраструктурная характеристика клеточных элементов белочной оболочки полового члена при болезни Пейрони. В кн.: Андрология и генитальная хирургия (тезисы науч. трудов). М.; 2002. 108.
  5. Mynderse L., Monga M. Oral therapy for Peyronie's disease. Int. J. Impotence Res. 2002; 14: 340-345.
  6. Hauck E. W., Schroeder-Printzen I., Weidner W. Konservative Therapie der Induratio penis plastica. Aktuel. Urol. 2001; 32: 44-47.
  7. Teasley G. H. Peyronie's disease; a new approach. J. Urol. (Baltimore) 1954; 71 (5): 611-614.
  8. Bodner H., Howard А. Н., Kaplan J. H. Peyronie's disease: cortisone-hyaluronidase-hydrocortisone therapy. J. Urol. (Baltimore) 1954; 400-403.
  9. Winter C. C., Khanna R. Peyronie's disease: results with dermo-jet injection of dexamethasone. J. Urol. (Baltimore) 1975; 114: 898-900.
  10. Williams G., Green N. A. The non-surgical treatment of Peyronie's disease. Br. J. Urol. 1980; 52: 392-395.
  11. Demey A., Chevallier D., Bondil P. et al. Is intracavernosal corticosteroid infiltration really useless in Peyronie's disease. Prog. Urol. 2006; 16 (1): 52-57.
  12. Levine L. A. Review of current nonsurgical management of Peyronie's disease. Int. J. Impot. Res. 2003; 15: S113-S120.
  13. Gelbard M. K., Walsh R. Collagenase for Peyronie's disease. Urol. Res. 1982; 10: 135-140.
  14. Gelbard M. K., Walsh R., Kaufman J. J. Collagenase for Peyronie's disease experimental studies. Urol. Res. 1982; 10: 135- 140.
  15. Gelbard M. K., Linkner A., Kaufman J. J. The use of collagenase in the treatment of Peyronie's disease. J. Urol. (Baltimore) 1985; 134: 280-283.
  16. Gelbard M. K., James K., Riach P., Dorey F. Collagenase vs. placebo in the treatment of Peyronie's disease: a double blind study. J. Urol. (Baltimore) 1993; 149: 56-58.
  17. Aggeler J., Frisch S. M., Werb Z. Changes in cell shape correlate with collagenase gene expression in rabbit synovial fibroblasts. J. Cell Biol. 1984; 98: 1662-1671.
  18. Roth M., Eickelberg O., Kohler E. et al. Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix. Proc. Natl. Acad. Sci. USA 1996; 93: 5478-5482.
  19. Lee R. C., Ping J. A. Calcium antagonists retard extracellular matrix production in connective tissue equivalent. J. Surg. Res. 1990; 49: 463-466.
  20. Levine L. A., Merrick P. F., Lee R. C. Intralesional verapamil injection for the treatment of Peyronie's disease. J. Urol. (Baltimore) 1994; 151: 1522-1524.
  21. Levine L. A., Estrada C. R. Intralesional verapamil for the treatment of Peyronie's disease: a review. Int. J. Impot. Res. 2002; 14: 324-328.
  22. Arena F., Peracchia G., di Stefano C. et al. Efficacia clinica del verapamil nella induratio penis plastica. Acta Biomed Ateneo Parmense. 1995; 66: 269-272.
  23. Lasser A., Vandenberg T. L., Vincent M. J., Hellstrom W. J. Intraplaque verapamil injection for treatment of Peyronie's disease. J. La St. Med. Soc. 1998; 150 (9): 431-434.
  24. Cavallini G., Modenini F., Vitali G. Open preliminary randomized prospective clinical trial of efficacy and safety of three different verapamil dilutions for intraplaque therapy of Peyronie's disease. Urology 2007. 69 (5): 950-954.
  25. Mirone V., Imbimbo C., Palmieri A., Fusco F. Our experience on the association of a new physical and medical therapy in patients suffering from induratio penis plastica. Eur. Urol. 1999; 36: 327-330.
  26. Bennett N. E., Guhring P., Mulhall J. P. Intralesional verapamil prevents the progression of Peyronie's disease. Urology 2007; 69: 1181-1184.
  27. Rehman J., Benet A., Melman A. Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single-blind study. Urology 1998; 51: 620-626.
  28. Nicolai M., Cipollone G., Iantorno R. et al. Intralesional verapamil injection versus placebo in Peyronie's disease. J. Urol. (Baltimore) 1998; 159: 117.
  29. Duncan M. R., Berman B. Differential regulation of glycosaminoglycan, fibronectin, and collagenase production in cultured human dermal fibroblasts by interferon-alpha, -beta, and -gamma. Arch. Dermatol. Res. 1989; 281 (1): 11-18.
  30. Duncan M. R., Berman B., Nseyo U. O. Regulation of the proliferation and biosynthetic activities of cultured human Peyronie's disease fibroblasts by interferons-alpha, -beta and -gamma. Scand. J. Urol. Nephrol. 1991; 25: 89-94.
  31. Benson R. C., Knoll L. D., Furlow W. L. Interferon-alpha-2b in the treatment of Peyronie's disease. J. Urol. (Baltimore) 1991; 145: 342A.
  32. Wegner H. E., Andreson R., Knipsel H. H., Miller K. Treatment of Peyronie's disease with local interferon-alpha-2b. Eur. Urol. 1995; 28: 236-240.
  33. Wegner H. E., Andreson R., Knipsel H. H., Miller K. Local interferon-alpha 2b is not an effective treatment in early-stage Peyronie's disease. Eur. Urol. 1997; 32: 190-193.
  34. Judge I. S., Widniewski Z. S. Intralesional interferon in the treatment of Peyronie's disease: a pilot study. Br. J. Urol. 1997; 79: 40-42.
  35. Brake M., Loertzer H., Horsch R., Keller H. Treatment of Peyronie's disease with local interferon-alpha-2b. Br. J. Urol. 2001; 87: 654-657.
  36. Astorga R., Cantero O., Contreras D. et al. Intralesional recombinant interferon alpha-2b in Peyronie's disease. Arch. Esp. Urol. 2000; 53: 665-671.
  37. Novak Т. Е. et al. Combined intralesional interferon alpha 2B and oral vitamin E in the treatment of Peyronie's disease. J. La St. Med. Soc. 2001; 153: 358-363.
  38. Hellstrom W. J., Kendirci M., Matern R. et al. Single-blind, multicenter placebo-controlled parallel study to asses the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment for Peyronie's disease. J. Urol. (Baltimore) 2006; 176: 394-398.
  39. Kendirci M., Usta M. F., Matern R. V. et al. The impact of intralesional interferon alpha-2b injection therapy on penile hemodynamics in men with Peyronie's disease. J. Sex. Med. 2005; 2 (5): 709-715.
  40. Мазо Е. Б., Муфагед М. Л., Иванченко Л. П. и др. Консервативное лечение болезни Пейрони в свете новых патогенетических данных. Урология 2006; 2: 32-37.
  41. Inal T., Tokatli Z., Akand M. et al. Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyroniefs disease: a randomized and prospective study. Urology 2006; 67 (5): 1038-1042.
  42. Gustafson H., Johansson B., Edsmyr F. Peyronie's disease: experience of local treatment with Orgotein. Eur. Urol. 1981; 7 (6): 346-348.
  43. Rossi A., Turco P., Vozza A. Treatment of induratio penis plastica with intralesional infiltration of orgotein. Our experience in 5 cases. G. Ital. Dermatol. Venereol. 1987; 122 (12): 675-677.
  44. Primus G. Orgotein in the treatment of plastic induration of the penis (Peyronie's disease). Int. Urol. Nephrol. 1993; 25 (2): 169-172.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2009 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies